মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

glaxosmithkline llc - ezogabine (unii: 12g01i6bbu) (ezogabine - unii:12g01i6bbu) - ezogabine 50 mg - potiga® is indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity [see warnings and precautions (5.1)] . none. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. potiga should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in animal studies, doses associated with maternal plasma exposures (auc) to ezogabine and its major circulating metabolite, n-acetyl metabolite of ezogabine (namr), similar to or below those expected in humans at the maximum recommended human dose (mrhd) of 1,200 mg per day produced developmental toxicity when administered to pregnant rats and rabbits. the maximum doses evaluated were limited by maternal toxicity (acute neurotoxicity). treatment of pregnant rats with ezogabine (oral doses

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

specialised therapeutics alim pty ltd - pemigatinib, quantity: 9 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a - pemigatinib has provisional approval in australia for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that has progressed after at least one prior line of systemic therapy. the decision to approve this indication has been made on the basis of overall response rate (orr) and duration of response (dor). continued approval of this indication depends on verification and description of benefit in confirmatory trial(s).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

specialised therapeutics alim pty ltd - pemigatinib, quantity: 4.5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a - pemigatinib has provisional approval in australia for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that has progressed after at least one prior line of systemic therapy. the decision to approve this indication has been made on the basis of overall response rate (orr) and duration of response (dor). continued approval of this indication depends on verification and description of benefit in confirmatory trial(s).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

specialised therapeutics alim pty ltd - pemigatinib, quantity: 13.5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a - pemigatinib has provisional approval in australia for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that has progressed after at least one prior line of systemic therapy. the decision to approve this indication has been made on the basis of overall response rate (orr) and duration of response (dor). continued approval of this indication depends on verification and description of benefit in confirmatory trial(s).

ইস্রায়েল - ইংরেজি - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

ইস্রায়েল - ইংরেজি - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 110 mg - dabigatran etexilate - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

ইস্রায়েল - ইংরেজি - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 150 mg - dabigatran etexilate - dabigatran etexilate - prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

কানাডা - ইংরেজি - Health Canada

boiron laboratoires - agar - drops - 2ch - agar 2ch - homeopathic products

কানাডা - ইংরেজি - Health Canada

dolisos laboratoires s.a. - agar - tablet - 1dh - agar 1dh - homeopathic products

কানাডা - ইংরেজি - Health Canada

boiron laboratoires - agar - tablet - 2ch - agar 2ch - homeopathic products